Saturday, April 26, 2014 7:27:27 AM
A zero sales/profits condition will not keep a NanoViricides, Inc. pps from skyrocketing to $500pps or $800pps (or more) once it performs well during clinical trials. Before the Clinical trials?...we will climb to $30pps and/or $70pps.
Take for example ICPT.
The stock of a little-known biotech company, Intercept Pharmaceuticals Inc., ICPT +59.89% nearly quadrupled Thursday after the company's liver-disease drug performed well in a clinical trial, marking the biggest one-day stock leap among Nasdaq Composite companies of a similar size since at least 2012.
Shares of New York-based Intercept—which has 45 employees and no products on the market—closed Thursday at $275.87 on the Nasdaq Stock Market, valuing the company at $5.3 billion. On Wednesday, the stock closed at $72.39 with a market capitalization of $1.4 billion.
That's the largest one-day jump among Nasdaq Composite companies with market values of over $1 billion since at least 2012, according to FactSet Research Systems Inc.
The drug, called obeticholic acid, or OCA, mimics a naturally occurring human bile acid that Intercept believes has insert-text-here. The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a clinical trial of the drug in patients with a condition known as nonalcoholic steatohepatitis, which involves fat accumulation in the liver that can cause inflammation and lead to the more serious conditions of cirrhosis and liver failure. The disease progresses over many years and often has no symptoms in the early stages.
There are no specific therapies for the disease, which affects 2% to 5% of Americans, according to the National Institutes of Health. Instead, physicians often recommend patients lose weight if they are overweight, improve their diets, exercise, and avoid alcohol and unnecessary medications.
NanoViricides, Inc. is ontrack to the Clinical Trials (2014-2015)
WEST HAVEN, Conn.--(BUSINESS WIRE)--Jul 23, 2012 - NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has retained Australian Biologics Pty. Ltd., a regulatory affairs consulting firm, to coordinate the regulatory review and approval to conduct the first human trials in Australia for Flucide™, the Company's broad-spectrum anti-influenza drug. Australian Biologics will also facilitate clinical trial site(s) selection and development of the clinical trials agreements.
source: http://www.drugs.com/clinical_trials/nanoviricides-retains-consulting-firm-expedite-first-flucide-human-trials-australia-14091.html
Yes, in the United States, each year on average 5% to 20% of the population gets the flu and more than 200,000 people are hospitalized from seasonal flu-related complications, this according to CDC stats.
We have read many times on this board that antiviral medicines that are used to treat or prevent the flu include oseltamivir (Tamiflu®) and zanamivir (Relenza®)and they are about 40% - 60% effective. Two other antiviral medicines, rimantadine (Flumadine®) and amantadine (Symmetrel®), were used in the past but are generally no longer effective because most flu viruses are now resistant to them.
The market size for anti-influenza drugs is currently estimated to be in several billions of dollars worldwide. The Company believes that if its FluCide® drug becomes available, the influenza drug market size could become substantially higher. The market size for over the counter (OTC) medications for control of influenza symptoms alone is approximately $2.1 billion dollars annually in the USA, and about £0.5 billion (about $1 billion) in the UK (source: http://www.mintel.com/press-centre/press-releases/410/consumers-cough-up-for-remedies-as-flu-season-starts-early). Similar large market sizes are reported for other countries across the globe. It is well known that when an effective treatment for a disease becomes available, the market size explodes and the novel effective treatment captures a substantial portion of the market.
source: http://www.nanoviricides.com/press%20releases/2013/Nanoviricides%20Announces%20Initiation%20of%20Toxicology%20Study%20of%20FluCide.html
source: http://www.nanoviricides.com/press%20releases/2013/Nanoviricides%20Announces%20Initiation%20of%20Toxicology%20Study%20of%20FluCide.html
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM